STOCK TITAN

Alignment Healthcare, Inc. (ALHC) SEC Filings, Jul-Aug 2026

ALHC NASDAQ

Welcome to our dedicated page for Alignment Healthcare SEC filings (Ticker: ALHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Alignment Healthcare, Inc.'s SEC filings document a Medicare Advantage operating company with common stock listed on Nasdaq under ALHC. Its Form 8-K reports furnish quarterly and annual operating results, health plan membership, revenue, adjusted gross profit, adjusted EBITDA, guidance updates and Regulation FD materials related to strategy, market position and Medicare Advantage quality ratings.

Proxy materials cover board elections, executive compensation, equity awards, pay-versus-performance data and shareholder voting matters. Registration statements, prospectus supplements and underwriting agreements describe secondary offerings of common stock by selling stockholders, the company's capital structure and related securities-law obligations.

Rhea-AI Summary

Invesco Ltd., as a parent holding company to its investment advisers, reports beneficial ownership of 10,365,640 shares of Alignment Healthcare Inc. common stock, representing 5.0% of the outstanding class. These shares are held of record by clients of Invesco’s advisory entities.

Invesco has sole voting power over 9,985,762 shares and sole dispositive power over all 10,365,640 shares, with no shared voting or dispositive authority. No single client has more than a 5% economic interest in the securities; the relevant clients are entitled to dividends and sale proceeds. Subsidiaries involved include Invesco Advisers, Inc., Invesco Asset Management Limited, and Invesco Capital Management LLC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
ownership
-
Rhea-AI Summary

Alignment Healthcare, Inc. insider John E. Kao, Chief Executive Officer and director, reported selling 298,000 shares of common stock on 2026-08-10 at a weighted-average price of $13.8818 per share, in multiple trades between $13.62 and $14.30. The sold shares are held indirectly through the JEK Trust, where Mr. Kao serves as trustee, leaving 790,766 common shares held indirectly after the sale. A separate entry shows 1,608,743 common shares held directly as of the same date. The filing states that the transactions were made pursuant to a Rule 10b5-1 trading plan adopted on 11/21/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Vanguard Portfolio Management LLC reports beneficial ownership of Alignment Healthcare Inc. common stock. It beneficially owns 11,874,585 shares, representing 5.74% of the outstanding common stock. Vanguard has sole voting power over 202,326 shares and sole dispositive power over 11,874,585 shares, with no shared voting or dispositive power.

The holdings reflect securities beneficially owned, or deemed beneficially owned, by Vanguard Portfolio Management LLC and specified Vanguard affiliates, including registered funds and other managed accounts. Vanguard entities have rights to dividends and sale proceeds on these securities, but no single other person’s interest exceeds 5% of the class.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
ownership
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.2%
Tags
quarterly report
-
Rhea-AI Summary

Alignment Healthcare reported results for the quarter ended June 30, 2026, with total revenue of $1,335.6 million, up 31.6% year-over-year, and health plan membership of approximately 294,100, up 31.5%. The company stated that performance surpassed the high end of its guidance across key metrics.

Adjusted gross profit was $182.9 million, up 35.3%, and income from operations was $42.1 million. Medical benefits ratio based on adjusted gross profit was 86.3%, improving about 40 basis points year-over-year. Adjusted EBITDA was $68.1 million, reflecting a 5.1% margin, while net income increased to $36.6 million from $15.7 million.

For the third quarter of 2026, the company forecasts revenue between $1,300 million and $1,320 million and adjusted EBITDA between $20 million and $30 million. For full-year 2026, revenue guidance is $5,195 million to $5,225 million and adjusted EBITDA guidance is $145 million to $163 million, alongside higher expected membership and adjusted gross profit.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.2%
Tags
current report
-
Rhea-AI Summary

BlackRock, Inc. reports beneficial ownership of Alignment Healthcare, Inc. common stock on a passive Schedule 13G/A basis. BlackRock reports beneficial ownership of 18,719,986 shares of common stock, representing 9.1% of the outstanding class.

BlackRock has sole voting power over 18,431,099 shares and sole dispositive power over all 18,719,986 shares, with no shared voting or shared dispositive power. Various underlying clients have economic interests in these shares, but no single person is stated to hold more than five percent of Alignment Healthcare’s total outstanding common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
ownership
Rhea-AI Summary

Alignment Healthcare, Inc. president Dawn Christine Maroney reported an option exercise and related stock sale. She exercised options to acquire 152,068 shares of common stock at $9.0600 per share and sold 177,068 shares in open-market transactions at a weighted-average price of $20.8281 per share under a Rule 10b5-1 trading plan adopted on 3/13/26, with individual sale prices ranging from $20.29 to $21.14. The exercised options, granted on 03/08/2022, vested 25% on each of the first four anniversaries of the grant date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

A Form 144 notice for ALHC covers a proposed sale of up to 177,068 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $3,753,841.60 and 206,733,823 shares outstanding. The shares include stock acquired via Exercise of Stock Options and RSU/PSU awards. It also lists prior 10b5-1 sales of 30,000 shares on May 15, 2026, for $482,567.00 and 30,000 shares on June 15, 2026, for $586,424.50.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

Alignment Healthcare, Inc. CEO and director John E. Kao reported open-market sales of 298,000 shares of common stock on July 10, 2026. The shares were sold in multiple transactions at weighted-average prices of $19.8122 and $20.6471 per share under a Rule 10b5-1 trading plan adopted on November 21, 2025, and include sales from a trust for which Mr. Kao serves as trustee.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

A selling holder has filed a notice to sell up to 596,000 shares of ALHC common stock through Morgan Stanley Smith Barney LLC Executive Financial Services. The proposed sale has an aggregate value of $12,533,880.00, with ALHC common stock listed on NASDAQ. ALHC had 206,733,823 shares of common stock outstanding as of this notice, which is a baseline figure, not the amount being sold. In the past three months, the same plan sold shares on three dates with specified share amounts and proceeds.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other

FAQ

How many Alignment Healthcare (ALHC) SEC filings are available on StockTitan?

StockTitan tracks 181 SEC filings for Alignment Healthcare (ALHC), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Alignment Healthcare (ALHC)?

The most recent SEC filing for Alignment Healthcare (ALHC) was filed on August 13, 2026.